[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539167":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":202,"collaborators":20,"id":204,"slug":20,"hasResults":205,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":20,"eligibilityCriteria":209,"healthyVolunteers":205,"sex":210,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":20,"studyType":216,"phases":217,"briefSummary":219,"conditions":220,"keywords":20,"overallStatus":177,"whyStopped":20,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":231},{"fullName":5,"class":6},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TQ05105 Tablets","EXPERIMENTAL","TQ05105 Tablets administered twice-daily. 28 days as a treatment cycle.",[13],"Drug: TQ05105 tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TQ05105 tablets","Rovadicitinib (TQ05105) is a novel, oral dual JAK 1\u002F2 and Rho-associated kinases (ROCK) 1\u002F2 inhibitor targeting inflammatory and fibrotic components of cGVHD.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"He Huang, PhD","CONTACT","13605714822","hehuangyu@126.com",[28,46,61,76,91,106,121,130,145,160,175,188],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Anhui Provincial Hospital","NOT_YET_RECRUITING","Hefei","Anhui","230001","China",{"type":36,"coordinates":37},"Point",[38,39],117.28083,31.86389,{"lat":39,"lon":38},[42],{"name":43,"role":24,"phone":44,"phoneExt":20,"email":45},"Lianxin Liu, PhD","15255456091","xiaoyuz@ustc.edu.cn",{"facility":47,"status":30,"city":48,"state":49,"zip":50,"country":34,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"The 940th hospital of joint logistics support force of Chinese people's liberation army","Lanzhou","Gansu","730050",{"type":36,"coordinates":52},[53,54],103.83987,36.05701,{"lat":54,"lon":53},[57],{"name":58,"role":24,"phone":59,"phoneExt":20,"email":60},"Tao Wu, PhD","13919939297","wutaozhen@yeah.net",{"facility":62,"status":30,"city":63,"state":64,"zip":65,"country":34,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Guangzhou First People's Hospital","Guangzhou","Guangdong","510180",{"type":36,"coordinates":67},[68,69],113.25,23.11667,{"lat":69,"lon":68},[72],{"name":73,"role":24,"phone":74,"phoneExt":20,"email":75},"Shunqing Wang, PhD","13437801998","drwangshq@medmail.com.cn",{"facility":77,"status":30,"city":78,"state":79,"zip":80,"country":34,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"The First Affiliated Hospital of Guangxi Medical University","Nanning","Guangxi","530021",{"type":36,"coordinates":82},[83,84],108.31667,22.81667,{"lat":84,"lon":83},[87],{"name":88,"role":24,"phone":89,"phoneExt":20,"email":90},"Zhongming Zhang, Master","15807801369","zzmmissyou@126.com",{"facility":92,"status":30,"city":93,"state":94,"zip":95,"country":34,"cosmosGeoPoint":96,"geoPoint":100,"contacts":101},"The Second Hospital of Hebei Medical University","Shijiazhuang","Hebei","050000",{"type":36,"coordinates":97},[98,99],114.47861,38.04139,{"lat":99,"lon":98},[102],{"name":103,"role":24,"phone":104,"phoneExt":20,"email":105},"Xuejun Zhang, PhD","13722781112","zhxjhbmu@126.com",{"facility":107,"status":30,"city":108,"state":109,"zip":110,"country":34,"cosmosGeoPoint":111,"geoPoint":115,"contacts":116},"Xiangyang Central Hospital","Xiangyang","Hubei","441021",{"type":36,"coordinates":112},[113,114],112.14479,32.0422,{"lat":114,"lon":113},[117],{"name":118,"role":24,"phone":119,"phoneExt":20,"email":120},"Guolin Yuan, PhD","18696231603","yuanguo1973@163.com",{"facility":122,"status":30,"city":123,"state":124,"zip":20,"country":34,"cosmosGeoPoint":20,"geoPoint":20,"contacts":125},"Tai'an Central Hospital","Taian","Shangdong",[126],{"name":127,"role":24,"phone":128,"phoneExt":20,"email":129},"Guanchen Bai, Bachelor","18653819776","bgcbgc1@163.com",{"facility":131,"status":30,"city":132,"state":133,"zip":134,"country":34,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine","Shanghai","Shanghai Municipality","200025",{"type":36,"coordinates":136},[137,138],121.45806,31.22222,{"lat":138,"lon":137},[141],{"name":142,"role":24,"phone":143,"phoneExt":20,"email":144},"Xiaoxia Hu, PhD","13795437259","hu_xiaoxia@126.com",{"facility":146,"status":30,"city":147,"state":148,"zip":149,"country":34,"cosmosGeoPoint":150,"geoPoint":154,"contacts":155},"The Second Affiliated Hospital of Xi'an Jiaotong University","Xi'an","Shannxi","710299",{"type":36,"coordinates":151},[152,153],108.92861,34.25833,{"lat":153,"lon":152},[156],{"name":157,"role":24,"phone":158,"phoneExt":20,"email":159},"Aili He, PhD","13891939962","heaili@xiju.edu.cn",{"facility":161,"status":30,"city":162,"state":163,"zip":164,"country":34,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"Hematology Hospital of the Chinese Academy of Medical Sciences","Tianjin","Tianjin Municipality","300020",{"type":36,"coordinates":166},[167,168],117.17667,39.14222,{"lat":168,"lon":167},[171],{"name":172,"role":24,"phone":173,"phoneExt":20,"email":174},"Er lie Jiang, PhD","022-23909180","jiangerlie@ihcams.ac.cn",{"facility":176,"status":177,"city":178,"state":179,"zip":180,"country":34,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"The First Affiliated Hospital, Zhejiang University School of Medicine","RECRUITING","Hangzhou","Zhejiang","310000",{"type":36,"coordinates":182},[183,184],120.16142,30.29365,{"lat":184,"lon":183},[187],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"facility":189,"status":30,"city":190,"state":179,"zip":191,"country":34,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"The Affiliated People's Hospital of Ningbo University","Ningbo","315040",{"type":36,"coordinates":193},[194,195],121.54945,29.87819,{"lat":195,"lon":194},[198],{"name":199,"role":24,"phone":200,"phoneExt":20,"email":201},"Ying Lu, Master","13486090834","rmluying@nbu.edu.cn",{"type":203,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100539167",false,"NCT06300320","A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease","A Randomized, Open-label, Multicenter Phase II Clinical Trial of Rovadicitinib in the Treatment of Third-line and Subsequent Moderate to Severe Chronic Graft-versus-host Disease (cGVHD).","Inclusion Criteria:\n\n* Voluntary and signed informed consent, good compliance;\n* Age 18-70 years old; Karnofsky Performance Scale (KPS) ≥60 points; Life expectancy ≥ 6months.\n* Received allogeneic hematopoietic stem cell transplantation;\n* Diagnosis of moderate-to-severe chronic graft-versus-host disease (cGVHD)\n* Received systemic therapies for cGVHD;\n* Stable dose of glucocorticoids, other immunosuppressant therapy received within 2 weeks prior to screening;\n* Absolute Neutrophil Count (ANC) ≥ 1.0×10 9\u002FL ；platelet count (PLT) ≥30×10 9 \u002FL; Hemoglobin ≥80g\u002FL; There were no obvious abnormalities in liver and kidney function and coagulation function;\n* Men and women of childbearing age agree to use contraceptive measures during the study period and within 6 months after the end of the study\n\nExclusion Criteria:\n\n* Currently present or occured other malignancies within 3 years prior to first administration;\n* Known or suspected active acute graft versus host disease (aGVHD);\n* Presence of infection requiring treatment within 7 days prior to randomization;\n* Failed allogeneic hematopoietic stem cell transplantation within 6 months or 2 prior allogeneic hematopoietic stem cell transplants;\n* Use of Janus-activated kinase (JAK) inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, or other, chemotherapeutic agents within 2 weeks prior to randomization;\n* Has a variety of factors that affect oral medications (e.g., inability to swallow, , intestinal obstruction, etc;\n* Those who have a history of psychotropic drug abuse and cannot be abstained from or have a mental disorder;\n* Have any severe or uncontrolled serious illness, including but not limited to uncontrolled hypertension, heart disease, hepatitis and epilepsy that require treatment;\n* Have any severe or uncontrolled serious illness, including but not limited to，uncontrolled hypertension heart disease, hepatitis and epilepsy that require treatment;\n* Those who are allergic to the study drug or its components;\n* Participation in other clinical trials or major surgery within 4 weeks prior to the first dose;\n* Subjects judged by the investigator to be unsuitable for enrollment;","ALL","18 Years","70 Years",{"count":214,"type":215},52,"ESTIMATED","INTERVENTIONAL",[218],"PHASE2","This is an open, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets in patients with chronic graft-versus-host disease",[221],"Chronic Graft Versus Host Disease","2025-02-09",{"date":224,"type":225},"2025-02-11","ACTUAL",{"date":227,"type":225},"2024-05-07",{"date":229,"type":215},"2026-04",{"name":5,"class":6},12]